{
    "clinical_study": {
        "@rank": "96033", 
        "brief_summary": {
            "textblock": "The purposes of this study are to determine a maximum tolerated dose and to evaluate the\n      safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia."
        }, 
        "brief_title": "Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Relapsed or refractory chronic lymphocytic leukemia.\n\n          2. Patients must have either intermediate or high risk chronic lymphocytic leukemia\n             according to the Rai Staging System.\n\n          3. Must have failed at least 1 prior chemotherapy regimen (at least 1 of which included\n             fludarabine) for CLL.\n\n          4. No prior therapy within 4 weeks prior to entering the study. Patients must have fully\n             recovered from the acute effects of prior therapy.\n\n          5. Platelet count = 75,000/mm3 , hemoglobin = 8 gm/dL.\n\n          6. Expected remaining life span > or = three months.\n\n          7. ECOG performance status 0 - 2.\n\n          8. 18 years or of legal age.\n\n          9. Male patients or non-pregnant and non-lactating female patients, who are either using\n             adequate birth control, are surgically sterile or post-menopausal.\n\n         10. Negative serum pregnancy test, if fertile female.\n\n         11. Willingness and ability to sign an informed consent document.\n\n        Exclusion Criteria:\n\n          1. Evidence of CNS involvement.\n\n          2. Other active malignancy or history of treatment of any malignancy (excluding\n             non-melanoma skin cancer) within the previous three years.\n\n          3. Previous therapy with Campath.\n\n          4. Patients with low-risk chronic lymphocytic leukemia according to the Rai Staging\n             System.\n\n          5. Concurrent immunotherapy.\n\n          6. Concurrent use of steroids.\n\n          7. Use of an investigational medication or device within 1 month of initiating study\n             therapy.\n\n          8. Patients who have had allogeneic bone marrow transplantation.\n\n          9. Total serum bilirubin above the upper limit of normal; serum creatinine above the\n             upper limit of normal.\n\n         10. AST or ALT > 2.5 times the upper limit of normal.\n\n         11. Any condition or any medication which may interfere with the conduct of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "15", 
        "firstreceived_date": "May 8, 2002", 
        "id_info": {
            "nct_id": "NCT00036257", 
            "org_study_id": "OSI-461-010"
        }, 
        "intervention": {
            "intervention_name": "CP-461", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic Lymphocytic Leukemia", 
            "Leukemia", 
            "CLL"
        ], 
        "lastchanged_date": "October 14, 2011", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Cancer Centers of Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albany", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "12208"
                    }, 
                    "name": "Albany Regional Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Mary Crowley Medical Research Center (US Oncology)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "Tyler Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99218"
                    }, 
                    "name": "Cancer Care Northwest"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036257"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cell Pathways", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "OSI Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2011"
    }, 
    "geocoordinates": {
        "Albany Regional Cancer Center": "42.653 -73.756", 
        "Cancer Care Northwest": "47.659 -117.426", 
        "Cancer Centers of Florida": "28.538 -81.379", 
        "Mary Crowley Medical Research Center (US Oncology)": "32.803 -96.77", 
        "Tyler Cancer Center": "32.351 -95.301"
    }
}